Publications by authors named "De-xiang Ji"
[Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2023
Article Synopsis
- - The study assessed the effectiveness of venetoclax-based regimens in treating acute myeloid leukemia (AML) through a retrospective analysis of 79 patients, focusing on their response rates and survival outcomes.
- - Among the patients, those with newly diagnosed unfit AML showed a higher complete remission/CR with incomplete hematologic recovery (CR/CRi) rate of 60.5%, compared to 27.8% in relapsed/refractory AML, with specific gene mutations offering significant benefits in the unfit cohort.
- - The median overall survival for all patients was 9.1 months, with unfit AML patients living significantly longer (14.1 months) than those with relapsed/refractory AML (
[Efficacy and Safety of Flumatinib in Treatment of Patients with Chronic Myeloid Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
August 2023
Objective: To analyze the efficacy and safety of flumatinib in the treatment of patients with chronic myeloid leukemia (CML).
Methods: The clinical data of 56 CML patients treated with flumatinib from January 2020 to December 2021 in the First Affiliated Hospital of Nanchang University were retrospectively analyzed. Patients were divided into three groups: 35 new diagnosed CML patients treated with flumatinib (group A), 10 patients with imatinib/dasatinib intolerance (group B) and 11 patients with imatinib/dasatinib resistance (group C) switched to flumatinib treatment, respectively.
[Incidence of JAK2V617F mutation in myeloproliferative diseases and its clinical significance].
Zhejiang Da Xue Xue Bao Yi Xue Ban
March 2010
Objective: To investigate the incidence of JAK2V617F gene point mutation in patients with myeloproliferatives diseases (MPD) and its clinical significance.
Methods: Genomic DNA from bone marrow and peripheral blood cells were extracted from 68 patients with MPD. Allele specific polymerase chain reaction was used to amplify the exon 12 of JAK2 gene which harbours V617F mutation.